Supporting Information for Original article

## Hyperthermia based individual *in situ* recombinant vaccine enhances lymph nodes drainage for *de novo* antitumor immunity

Cuixia Zheng<sup>b,†</sup>, Xinxin Liu<sup>a,b,†</sup>, Yueyue Kong<sup>b</sup>, Lei Zhang<sup>d</sup>, Qingling Song<sup>b</sup>, Hongjuan Zhao<sup>b</sup>, Lu Han<sup>b</sup>, Jiannan Jiao<sup>b</sup>, Qianhua Feng<sup>b,c,\*</sup>, Lei Wang<sup>a,b,c,e,\*</sup>

<sup>a</sup>Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China

<sup>b</sup>School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

<sup>c</sup>Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China <sup>d</sup>Department of gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China

<sup>e</sup>Tumor Immunity and Biomaterials Advanced Medical Center, Zhengzhou University, Luoyang 471009, China


Received 7 November 2021; received in revised form 10 January 2022; accepted 12 February 2022

\*Corresponding authors. Tel: +86 371 67781910 (Qianhua Feng), +86 371 67781908 (Lei Wang).

E-mail addresses: fengqianhua@zzu.edu.cn (Qianhua Feng), wanglei1@zzu.edu.cn (Lei Wang).

<sup>†</sup>These authors made equal contributions to this work.

Running title: Individual in situ recombinant vaccine for enhancing immunotherapy



**Figure S1** (A) Particle size and (B) Zeta potential of AuNCs, AuNCs/SV, FA-TSL/AuNCs/SV.




Figure S2 UV–Vis spectrum.





Figure S3 The stability of FA-TSL/AuNCs/SV.



**Figure S4** Thermal images of water, Au (20 and 50  $\mu$ g/mL) exposed to 808 nm laser irradiation (1.5 W/cm<sup>2</sup>).





Figure S5 Photostability of FA-TSL/AuNCs/SV during 808 nm laser irradiation (1.5  $W/cm^2$ ).



**Figure S6** Size (A) and zeta potential (B) of AuNCs/SV, FA-TSL/AuNCs/SV and FA-TSL/AuNCs/SV+laser (n = 3).





Figure S7 Cellular uptake (scale bar =  $100 \ \mu m$ ).



**Figure S8** The flow cytometry analysis of uptake efficiency on BMDCs (n = 3).






Figure S9 CLSM image of tumor cells expressing mCherry-Rab5 and EGFP-Rab7a in BMDCs treated with AuNCs/TDPAs and AuNCs/SV/TDPAs. Scale bar =  $10 \mu m$ .



**Figure S10** AuNCs/SV/FITC–OVA shows prolonged antigen retention in BMDC compared with AuNCs/ FITC–OVA. Scale bar =  $50 \mu m$ .



**Figure S11** Quantitative analysis of  $CD86^+CD80^+$  DCs (n = 3).





Figure S12 Biodistribution of IR780 and FA-TSL/AuNCs/IR780.



**Figure S13** Representative images of recombinant vaccine drainage to LNs *via* lymphatic vessels (red, podoplanin; green, AuNCs/FITC; blue, DAPI). Scale bar = 100 mM.







Figure S14 (A) In vivo IR thermal images and (B) corresponding temperature changes.



**Figure S15** Body weight (n = 6).



**Figure S16** H&E staining of main organs (scale bar =  $200 \ \mu m$ ).



**Figure S17** Serum biochemical analysis and blood routine data (n = 3).






Figure S18 The expression of CRT and HMGB1 in tumor tissues (scale bar =  $200 \mu m$ ).



**Figure S19** (A) DCs maturation and (B) CTLs in tumor tissue (n = 3).



**Figure S20**  $T_{EM}$  (gated on CD3<sup>+</sup> and CD8<sup>+</sup>) in spleens (n = 3).